| 產(chǎn)品詳情 |
| Edit |   |
|---|
| Product Name | Rebastinib (DCC-2036) |
|---|
| Description | DCC-2036 (Rebastinib) is an inhibitor of Bcr-Abl with IC50 of 0.8 nM and 4 nM for Abl1(WT) and Abl1(T315I), respectively. MW: 553.59. Purity >98% |
|---|
| Size | 5 mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | DCC-2036; DCC-2036; DCC2036; Bcr-Abl inhibitor; Bcr-abl inhibitor; 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide |
|---|
| Gene, Accession, CAS # | CAS: 1020172-07-9 |
|---|
| Catalog # | B1619-5 |
|---|
| Price | |
|---|
| Order / More Info | Rebastinib (DCC-2036) from BIOVISION, INC. |
|---|
| Product Specific References | n/a |
|---|
| 產(chǎn)品資料 |
|
|
| | <![CDATA[<strong id="itm00"><address id="itm00"></address></strong>]]><![CDATA[<th id="itm00"></th>]]>
<![CDATA[<acronym id="itm00"><label id="itm00"></label></acronym>]]>
|
| | |
|
|
|
| | |